Patient 3, a 68-year-old female never-smoker, had EGFR-mutated clinical stage IIa (cT2bN0M0) lepidic-predominant adenocarcinoma, for which she received gefitinib that was stopped after a month because of skin toxicity. The gene discussed is EGFR; the disease is adenocarcinoma.